查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2035372

組織工程材料市場預測至2034年－按材料、支架類型、應用、技術、最終用戶和地區分類的全球分析

Tissue Engineering Materials Market Forecasts to 2034 - Global Analysis By Material, Scaffold Type, Application, Technology, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球組織工程材料市場規模將達到 257.3 億美元，在預測期內將以 14.5% 的複合年成長率成長，到 2034 年將達到 764.4 億美元。

組織工程材料是用於修復、替代或再生受損組織和器官的生物材料。這些材料包括可生物分解的聚合物、水凝膠、支架以及促進細胞增殖和組織形成的生物活性物質。它們廣泛應用於再生醫學、傷口護理和器官重組。這些材料透過模擬天然生物環境來促進癒合並與人體整合。生物技術和材料科學的進步正在推動創新，使組織工程的應用能夠實現更有效、更個人化的醫療治療。

生物材料和支架的進展

研究人員正在開發模擬活體組織環境的先進天然和合成材料。這些創新能夠改善細胞黏附、增生和分化，進而提升治療效果。具有生物活性的支架進一步加速組織再生。奈米技術與智慧生物材料的融合正在提高人工結構的精確度。隨著技術的不斷進步，生物材料和支架仍是推動市場擴張的核心動力。

醫療核准中的監管障礙

獲得醫療核准需要大規模的臨床試驗和漫長的檢驗期。企業在將新產品推向市場時面臨高昂的成本和漫長的等待。區域監管的不確定性進一步加劇了全球企業的複雜性。中小企業往往難以滿足合規要求，這限制了創新。因此，監管障礙阻礙了市場成長。

3D生物列印技術的發展

生物列印技術能夠利用生物材料精確建構複雜的組織結構。這項技術透過根據個別患者的需求量身定做結構，為個人化醫療提供支援。列印技術的進步正在拓展其在器官再生和藥物測試等領域的應用。生物技術公司與研究機構之間的合作正在加速其商業化進程。隨著生物列印技術的日趨成熟，組織工程材料的應用預計將顯著增加。

關於長期成功率的數據有限。

許多臨床應用仍處於早期階段，關於其持久性的證據有限。與宿主組織長期整合的不確定性引起了監管機構和醫療專業人員的擔憂。數據的缺乏減緩了其在主流醫療機構的應用。投資者在沒有確鑿結果的情況下也不願投資。如果沒有可靠的縱向研究，成功率數據的缺乏很可能仍將是市場接受度面臨的一大挑戰。

新型冠狀病毒（COVID-19）的影響

新冠疫情擾亂了組織工程領域的研究和臨床試驗。供應鏈中斷導致生物材料和實驗室設備的供應延遲。然而，這場危機凸顯了再生醫學在增強醫療韌性的重要性。生物醫學研究經費的增加加速了生物材料的創新。遠端協作和數位化平台即使在限制下也支持了研發工作的持續進行。總而言之，儘管新冠疫情帶來了短期挑戰，但也增強了組織工程材料的長期發展機會。

在預測期內，天然生物材料領域預計將佔據最大佔有率。

由於天然生物材料能夠忠實地模擬生物組織的環境，預計在預測期內，其市場佔有率將佔據最大。膠原蛋白、明膠和藻酸鹽等天然材料具有優異的生物相容性。它們促進細胞增殖和整合的能力能夠改善治療效果。監管機構對天然生物材料的核准進一步鞏固了其優勢。對生物活性天然支架的持續研究正在拓展其應用範圍。

在預測期內，3D生物列印領域預計將呈現最高的複合年成長率。

在預測期內，由於3D生物列印在再生醫學領域具有變革性潛力，該領域預計將呈現最高的成長率。生物列印能夠精確地將生物材料分層，從而建構複雜的組織結構。這項技術支持個人化醫療，並加速藥物研發進程。對生物列印新創企業的投資增加正在推動創新和商業化。在器官再生和傷口護理領域的廣泛應用進一步刺激了市場需求。

市佔率最大的地區

在預測期內，北美地區預計將佔據最大的市場佔有率，這得益於其先進的研究基礎設施和健全的資金籌措體系。領先的生物技術公司和學術機構的存在進一步鞏固了該地區的領先地位。儘管法律規範較為嚴格，但它為商業化提供了一條清晰的路徑。對再生醫學的大量投資正在加速生物材料的應用。消費者對創新醫療保健解決方案的需求正在推動進一步的成長。

複合年成長率最高的地區

在預測期內，亞太地區預計將呈現最高的複合年成長率，這主要得益於醫療保健的快速發展和政府主導的研究舉措。中國、印度和日本等國正大力投資再生醫學。對價格合理且創新治療方法的需求不斷成長，為這些療法的應用創造了有利條件。大學與生物技術公司之間的區域合作正在加速創新。不斷完善的醫療基礎設施正在支持先進生物材料的商業化。

免費客製化服務

所有購買此報告的客戶均可享受以下免費自訂選項之一。

  • 企業概況
    • 對其他市場參與企業（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域細分
    • 我們根據客戶要求提供主要國家和地區的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 透過產品系列、地域覆蓋和策略聯盟對標領先企業。

目錄

第1章：執行摘要

  • 市場概覽及主要亮點
  • 促進因素、挑戰與機遇
  • 競爭格局概述
  • 戰略洞察與建議

第2章：研究框架

  • 研究目標和範圍
  • 相關人員分析
  • 研究假設和限制
  • 調查方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 成長機會和重點投資領域
  • 工業威脅與風險評估
  • 技術與創新展望
  • 新興市場/高成長市場
  • 監管和政策環境
  • 新冠疫情的影響及復甦前景

第4章：競爭環境與策略評估

  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要公司市佔率分析
  • 產品基準評效和效能比較

第5章 全球組織工程材料市場：依材料分類

  • 天然生物材料
  • 合成生物材料
  • 混合生物材料
  • 去細胞基質
  • 其他

第6章 全球組織工程材料市場：依支架類型分類

  • 水凝膠支架
  • 纖維支架
  • 多孔支架
  • 3D生物列印支架
  • 其他

第7章 全球組織工程材料市場：依應用領域分類

  • 皮膚/傷口護理
  • 骨/軟骨再生
  • 心血管組織工程
  • 神經組織工程
  • 其他

第8章 全球組織工程材料市場：依技術分類

  • 3D生物列印
  • 奈米材料和奈米纖維
  • 幹細胞整合
  • 生長因子輸送系統
  • 其他

第9章 全球組織工程材料市場：依最終使用者分類

  • 醫院和診所
  • 生技公司
  • 製藥公司
  • 研究機構
  • 學術機構
  • 其他

第10章 全球組織工程材料市場：依地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 其他
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲地區

第11章 策略市場資訊

  • 工業價值網路和供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第12章：產業趨勢與策略舉措

  • 併購
  • 夥伴關係、聯盟、合資企業
  • 新產品發布和認證
  • 擴大生產能力和投資
  • 其他策略舉措

第13章：公司簡介

  • Thermo Fisher Scientific Inc.
  • Danaher Corporation
  • Becton, Dickinson and Company（BD）
  • Stryker Corporation
  • Zimmer Biomet Holdings, Inc.
  • Medtronic plc
  • 3M Company
  • Baxter International Inc.
  • Collagen Matrix, Inc.
  • Integra LifeSciences Holdings Corporation
  • Cook BIoTech Incorporated
  • Organogenesis Holdings Inc.
  • Matricel GmbH
  • Tissue Regenix Group plc
  • Vericel Corporation
  • Regen Lab SA
  • DSM Biomedical
Product Code: SMRC35564

According to Stratistics MRC, the Global Tissue Engineering Materials Market is accounted for $25.73 billion in 2026 and is expected to reach $76.44 billion by 2034 growing at a CAGR of 14.5% during the forecast period. Tissue Engineering Materials are biomaterials used to repair, replace, or regenerate damaged tissues and organs. These materials include biodegradable polymers, hydrogels, scaffolds, and bioactive compounds that support cell growth and tissue formation. They are widely used in regenerative medicine, wound healing, and organ reconstruction. These materials mimic natural biological environments to promote healing and integration with the body. Advances in biotechnology and material science are driving innovation, enabling more effective and personalized medical treatments in tissue engineering applications.

Market Dynamics:

Driver:

Advancements in biomaterials and scaffolds

Researchers are developing advanced natural and synthetic materials that mimic native tissue environments. These innovations improve cell adhesion, proliferation, and differentiation, enhancing therapeutic outcomes. Scaffolds designed with bioactive properties further accelerate tissue regeneration. The integration of nanotechnology and smart biomaterials adds precision to engineered constructs. As advancements continue, biomaterials and scaffolds remain a central driver of market expansion.

Restraint:

Regulatory hurdles in medical approvals

Medical approvals require extensive clinical trials and long validation timelines. Companies face high costs and delays in bringing new products to market. Regulatory uncertainty across regions adds complexity for global players. Smaller firms often struggle to meet compliance requirements, limiting innovation. Consequently, regulatory hurdles act as a restraint on market growth.

Opportunity:

Growth in 3D bioprinting technologies

Bioprinting enables precise fabrication of complex tissue structures using biomaterials. This technology supports personalized medicine by tailoring constructs to patient-specific needs. Advances in printing techniques are expanding applications in organ regeneration and drug testing. Partnerships between biotech firms and research institutions are accelerating commercialization. As bioprinting matures, it will significantly enhance the adoption of tissue engineering materials.

Threat:

Limited long-term success rate data

Many clinical applications remain in early stages, with limited evidence of durability. Uncertainty regarding long-term integration with host tissues raises concerns among regulators and practitioners. This gap in data slows adoption in mainstream healthcare. Investors also hesitate to commit without proven outcomes. Without robust longitudinal studies, limited success rate data remains a challenge for market acceptance.

Covid-19 Impact:

The Covid-19 pandemic disrupted research and clinical trials in tissue engineering. Supply chain interruptions slowed the availability of biomaterials and laboratory equipment. However, the crisis also highlighted the importance of regenerative medicine in healthcare resilience. Increased funding for biomedical research accelerated innovation in biomaterials. Remote collaborations and digital platforms supported ongoing development despite restrictions. Overall, Covid-19 created short-term challenges but reinforced long-term opportunities for tissue engineering materials.

The natural biomaterials segment is expected to be the largest during the forecast period

The natural biomaterials segment is expected to account for the largest market share during the forecast period as they closely replicate native tissue environments. Natural materials such as collagen, gelatin, and alginate provide superior biocompatibility. Their ability to support cell growth and integration enhances therapeutic outcomes. Regulatory acceptance of natural biomaterials further strengthens their dominance. Continuous research into bioactive natural scaffolds expands their applications.

The 3D bioprinting segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the 3D bioprinting segment is predicted to witness the highest growth rate due to its transformative potential in regenerative medicine. Bioprinting enables precise layering of biomaterials to create complex tissue structures. The technology supports personalized therapies and accelerates drug discovery. Rising investments in bioprinting startups fuel innovation and commercialization. Expanding applications in organ regeneration and wound healing amplify demand.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share owing to its advanced research infrastructure and strong funding ecosystem. The presence of leading biotech firms and academic institutions reinforces regional dominance. Regulatory frameworks, while stringent, provide clear pathways for commercialization. High investments in regenerative medicine accelerate adoption of biomaterials. Consumer demand for innovative healthcare solutions further boosts growth.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR driven by rapid healthcare expansion and government-backed research initiatives. Countries such as China, India, and Japan are investing heavily in regenerative medicine. Rising demand for affordable and innovative therapies creates fertile ground for adoption. Regional collaborations between universities and biotech firms accelerate innovation. Expanding healthcare infrastructure supports commercialization of advanced biomaterials.

Key players in the market

Some of the key players in Tissue Engineering Materials Market include Thermo Fisher Scientific Inc., Danaher Corporation, Becton, Dickinson and Company, Stryker Corporation, Zimmer Biomet Holdings, Inc., Medtronic plc, 3M Company, Baxter International Inc., Collagen Matrix, Inc., Integra LifeSciences Holdings Corporation, Cook Biotech Incorporated, Organogenesis Holdings Inc., Matricel GmbH, Tissue Regenix Group plc, Vericel Corporation, Regen Lab SA and DSM Biomedical.

Key Developments:

In January 2026, Medtronic and several AI-focused biotech firms entered Strategic Alliances to integrate predictive modeling into regenerative bone repair. This follows Medtronic's focus on "AI-assisted diagnostics" as a core growth pillar for its 2026 tech trends.

In March 2025, Japan Tissue Engineering Co., Ltd. strengthened its Strategic Collaboration with Teijin Limited. This partnership utilizes Teijin's structural analysis division to improve manufacturing efficiency and research for cultured tissue products.

Materials Covered:

  • Natural Biomaterials
  • Synthetic Biomaterials
  • Hybrid Biomaterials
  • Decellularized Matrices
  • Other Materials

Scaffold Types Covered:

  • Hydrogel Scaffolds
  • Fibrous Scaffolds
  • Porous Scaffolds
  • 3D Bioprinted Scaffolds
  • Other Scaffold Types

Applications Covered:

  • Skin & Wound Healing
  • Bone & Cartilage Regeneration
  • Cardiovascular Tissue Engineering
  • Neural Tissue Engineering
  • Other Applications

Technologies Covered:

  • 3D Bioprinting
  • Nanomaterials & Nanofibers
  • Stem Cell Integration
  • Growth Factor Delivery Systems
  • Other Technologies

End Users Covered:

  • Hospitals & Clinics
  • Biotechnology Companies
  • Pharmaceutical Companies
  • Research Institutes
  • Academic Institutions
  • Other End Users

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Tissue Engineering Materials Market, By Material

  • 5.1 Natural Biomaterials
  • 5.2 Synthetic Biomaterials
  • 5.3 Hybrid Biomaterials
  • 5.4 Decellularized Matrices
  • 5.5 Other Materials

6 Global Tissue Engineering Materials Market, By Scaffold Type

  • 6.1 Hydrogel Scaffolds
  • 6.2 Fibrous Scaffolds
  • 6.3 Porous Scaffolds
  • 6.4 3D Bioprinted Scaffolds
  • 6.5 Other Scaffold Types

7 Global Tissue Engineering Materials Market, By Application

  • 7.1 Skin & Wound Healing
  • 7.2 Bone & Cartilage Regeneration
  • 7.3 Cardiovascular Tissue Engineering
  • 7.4 Neural Tissue Engineering
  • 7.5 Other Applications

8 Global Tissue Engineering Materials Market, By Technology

  • 8.1 3D Bioprinting
  • 8.2 Nanomaterials & Nanofibers
  • 8.3 Stem Cell Integration
  • 8.4 Growth Factor Delivery Systems
  • 8.5 Other Technologies

9 Global Tissue Engineering Materials Market, By End User

  • 9.1 Hospitals & Clinics
  • 9.2 Biotechnology Companies
  • 9.3 Pharmaceutical Companies
  • 9.4 Research Institutes
  • 9.5 Academic Institutions
  • 9.6 Other End Users

10 Global Tissue Engineering Materials Market, By Geography

  • 10.1 North America
    • 10.1.1 United States
    • 10.1.2 Canada
    • 10.1.3 Mexico
  • 10.2 Europe
    • 10.2.1 United Kingdom
    • 10.2.2 Germany
    • 10.2.3 France
    • 10.2.4 Italy
    • 10.2.5 Spain
    • 10.2.6 Netherlands
    • 10.2.7 Belgium
    • 10.2.8 Sweden
    • 10.2.9 Switzerland
    • 10.2.10 Poland
    • 10.2.11 Rest of Europe
  • 10.3 Asia Pacific
    • 10.3.1 China
    • 10.3.2 Japan
    • 10.3.3 India
    • 10.3.4 South Korea
    • 10.3.5 Australia
    • 10.3.6 Indonesia
    • 10.3.7 Thailand
    • 10.3.8 Malaysia
    • 10.3.9 Singapore
    • 10.3.10 Vietnam
    • 10.3.11 Rest of Asia Pacific
  • 10.4 South America
    • 10.4.1 Brazil
    • 10.4.2 Argentina
    • 10.4.3 Colombia
    • 10.4.4 Chile
    • 10.4.5 Peru
    • 10.4.6 Rest of South America
  • 10.5 Rest of the World (RoW)
    • 10.5.1 Middle East
      • 10.5.1.1 Saudi Arabia
      • 10.5.1.2 United Arab Emirates
      • 10.5.1.3 Qatar
      • 10.5.1.4 Israel
      • 10.5.1.5 Rest of Middle East
    • 10.5.2 Africa
      • 10.5.2.1 South Africa
      • 10.5.2.2 Egypt
      • 10.5.2.3 Morocco
      • 10.5.2.4 Rest of Africa

11 Strategic Market Intelligence

  • 11.1 Industry Value Network and Supply Chain Assessment
  • 11.2 White-Space and Opportunity Mapping
  • 11.3 Product Evolution and Market Life Cycle Analysis
  • 11.4 Channel, Distributor, and Go-to-Market Assessment

12 Industry Developments and Strategic Initiatives

  • 12.1 Mergers and Acquisitions
  • 12.2 Partnerships, Alliances, and Joint Ventures
  • 12.3 New Product Launches and Certifications
  • 12.4 Capacity Expansion and Investments
  • 12.5 Other Strategic Initiatives

13 Company Profiles

  • 13.1 Thermo Fisher Scientific Inc.
  • 13.2 Danaher Corporation
  • 13.3 Becton, Dickinson and Company (BD)
  • 13.4 Stryker Corporation
  • 13.5 Zimmer Biomet Holdings, Inc.
  • 13.6 Medtronic plc
  • 13.7 3M Company
  • 13.8 Baxter International Inc.
  • 13.9 Collagen Matrix, Inc.
  • 13.10 Integra LifeSciences Holdings Corporation
  • 13.11 Cook Biotech Incorporated
  • 13.12 Organogenesis Holdings Inc.
  • 13.13 Matricel GmbH
  • 13.14 Tissue Regenix Group plc
  • 13.15 Vericel Corporation
  • 13.16 Regen Lab SA
  • 13.17 DSM Biomedical

List of Tables

  • Table 1 Global Tissue Engineering Materials Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Tissue Engineering Materials Market, By Material (2023-2034) ($MN)
  • Table 3 Global Tissue Engineering Materials Market, By Natural Biomaterials (2023-2034) ($MN)
  • Table 4 Global Tissue Engineering Materials Market, By Synthetic Biomaterials (2023-2034) ($MN)
  • Table 5 Global Tissue Engineering Materials Market, By Hybrid Biomaterials (2023-2034) ($MN)
  • Table 6 Global Tissue Engineering Materials Market, By Decellularized Matrices (2023-2034) ($MN)
  • Table 7 Global Tissue Engineering Materials Market, By Other Materials (2023-2034) ($MN)
  • Table 8 Global Tissue Engineering Materials Market, By Scaffold Type (2023-2034) ($MN)
  • Table 9 Global Tissue Engineering Materials Market, By Hydrogel Scaffolds (2023-2034) ($MN)
  • Table 10 Global Tissue Engineering Materials Market, By Fibrous Scaffolds (2023-2034) ($MN)
  • Table 11 Global Tissue Engineering Materials Market, By Porous Scaffolds (2023-2034) ($MN)
  • Table 12 Global Tissue Engineering Materials Market, By 3D Bioprinted Scaffolds (2023-2034) ($MN)
  • Table 13 Global Tissue Engineering Materials Market, By Other Scaffold Types (2023-2034) ($MN)
  • Table 14 Global Tissue Engineering Materials Market, By Application (2023-2034) ($MN)
  • Table 15 Global Tissue Engineering Materials Market, By Skin & Wound Healing (2023-2034) ($MN)
  • Table 16 Global Tissue Engineering Materials Market, By Bone & Cartilage Regeneration (2023-2034) ($MN)
  • Table 17 Global Tissue Engineering Materials Market, By Cardiovascular Tissue Engineering (2023-2034) ($MN)
  • Table 18 Global Tissue Engineering Materials Market, By Neural Tissue Engineering (2023-2034) ($MN)
  • Table 19 Global Tissue Engineering Materials Market, By Other Applications (2023-2034) ($MN)
  • Table 20 Global Tissue Engineering Materials Market, By Technology (2023-2034) ($MN)
  • Table 21 Global Tissue Engineering Materials Market, By 3D Bioprinting (2023-2034) ($MN)
  • Table 22 Global Tissue Engineering Materials Market, By Nanomaterials & Nanofibers (2023-2034) ($MN)
  • Table 23 Global Tissue Engineering Materials Market, By Stem Cell Integration (2023-2034) ($MN)
  • Table 24 Global Tissue Engineering Materials Market, By Growth Factor Delivery Systems (2023-2034) ($MN)
  • Table 25 Global Tissue Engineering Materials Market, By Other Technologies (2023-2034) ($MN)
  • Table 26 Global Tissue Engineering Materials Market, By End User (2023-2034) ($MN)
  • Table 27 Global Tissue Engineering Materials Market, By Hospitals & Clinics (2023-2034) ($MN)
  • Table 28 Global Tissue Engineering Materials Market, By Biotechnology Companies (2023-2034) ($MN)
  • Table 29 Global Tissue Engineering Materials Market, By Pharmaceutical Companies (2023-2034) ($MN)
  • Table 30 Global Tissue Engineering Materials Market, By Research Institutes (2023-2034) ($MN)
  • Table 31 Global Tissue Engineering Materials Market, By Academic Institutions (2023-2034) ($MN)
  • Table 32 Global Tissue Engineering Materials Market, By Other End Users (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) are also represented in the same manner as above.